Zydus Completes Acquisition of Agenus Manufacturing Sites, Forms Zylidac Bio
Zydus Lifesciences completed acquisition of Agenus's Emeryville and Berkeley biologics manufacturing facilities through asset and share purchase and licensing agreements, forming U.S. CDMO subsidiary Zylidac Bio LLC. The deal monetizes Agenus's manufacturing assets and secures U.S. capacity for Phase 3 immuno-oncology candidates Botensilimab and Balstilimab.
1. Completion of Asset and Share Purchase Agreements
Zydus Lifesciences Limited has finalized the Asset Purchase Agreement, Share Purchase Agreement and an exclusive Licensing Agreement with Agenus Inc., following receipt of all required regulatory approvals, including clearance from the Committee on Foreign Investment in the United States (CFIUS). Through this transaction, Zydus acquires Agenus’s state-of-the-art biologics manufacturing facilities in Emeryville and Berkeley, California. All operations and assets will be consolidated into a newly formed U.S. subsidiary, Zylidac Bio LLC, establishing Zydus’s advanced CDMO footprint in North America.
2. Strategic Focus for Agenus’s Immunotherapy Pipeline
Under the terms of the exclusive manufacturing agreement, Zylidac Bio LLC will serve as the sole provider for drug substance and drug product production for Agenus’s Phase 3 immuno-oncology candidates, Botensilimab (BOT) and Balstilimab (BAL). Agenus will monetize its manufacturing assets in the U.S., while securing dedicated, high-quality biologics capacity to support late-stage development and global patient access. The deal also grants Zydus exclusive commercialization rights for BOT and BAL in India and Sri Lanka, allowing Agenus to concentrate resources on clinical and commercial execution of its immunotherapy pipeline.
3. Regulatory and Market Implications
The formation of Zylidac Bio LLC creates a secure domestic manufacturing option that complies with the BIOSECURE Act enacted December 18, 2025, which restricts executive agencies from contracting with ‘Biotechnology Companies of Concern.’ By providing a California-based, compliant supply-chain solution, Zydus addresses biopharma demand for domestic, high-quality biologics production. Additionally, Agenus’s equity position was reinforced through an investment by Zydus’s venture arm, Zynext Ventures, aligning both companies on future biosimilar and innovative biologics initiatives.
4. Analyst Upgrade Signals Growing Optimism
Agenus has been upgraded to a Zacks Rank #2 (Buy), reflecting increased analyst confidence in the company’s earnings trajectory post-transaction. The upgrade highlights the expected margin benefits and cash flow generation from divested manufacturing operations, as well as upside potential tied to pipeline advancements for BOT and BAL. This rating change may attract institutional interest and support share performance in the near term.